Von Hippel-Lindau Disease Genetic Testing

About this condition

Von Hippel-Lindau Disease

Von Hippel-Lindau (VHL) syndrome is caused by germline pathogenic variants in VHL, a gene encoding a protein component of an E3 ubiquitin ligase complex. Under normal oxygen, pVHL targets hypoxia-inducible factor (HIF) for degradation. When pVHL is dysfunctional, HIF accumulates constitutively, activating genes involved in angiogenesis, cell proliferation, and glucose metabolism — even in the presence of adequate oxygen. This pseudo-hypoxic state drives tumor formation specifically in highly vascularized organs. VHL follows Knudson's two-hit tumor suppressor model: the inherited germline variant inactivates one allele; somatic loss of the remaining allele initiates tumorigenesis.

Von Hippel-Lindau syndrome affects approximately 1 in 30,000–50,000 individuals, with penetrance exceeding 90% by age 65. The syndrome is characterized by multiple tumor types: hemangioblastomas of the brain, spinal cord, and retina (present in 60–80% of carriers), renal cysts and clear cell renal cell carcinoma (occurring in ~70%, the leading cause of mortality), pheochromocytoma/paraganglioma (10–20%), pancreatic neuroendocrine tumors and cysts, endolymphatic sac tumors, and epididymal/broad ligament cystadenomas. Approximately 10% of cases are de novo variants. Average age of VHL diagnosis is 26 years, with range from infancy to the seventh decade.

Identifying a VHL pathogenic variant dramatically changes clinical management. It triggers comprehensive lifelong surveillance beginning in childhood: annual retinal examination from age 1, annual blood pressure monitoring from age 5, annual abdominal MRI from age 15, and biennial brain/spine MRI. This surveillance approach catches renal cell carcinomas and pheochromocytomas at early stages when kidney-sparing surgery is possible, preserving renal function through multiple interventions over a lifetime. Belzutifan, an FDA-approved HIF-2α inhibitor, offers targeted therapy for VHL-associated renal cell carcinoma. Cascade testing identifies relatives at risk before tumors develop.

VHL genotype-phenotype correlations are clinically important: Type 1 variants (no pheochromocytoma risk) have different surveillance protocols than Type 2A/2B/2C variants (pheochromocytoma risk, requiring additional screening).

Gene locus: VHL (3p25.3)

The VHL gene is small, but approximately 20% of pathogenic variants are large deletions — requiring specialized analysis standard sequencing does not provide.

VHL deletions require deletion-duplication analysis standard panels lack

VHL is a relatively small gene (3 exons), which typically allows high detection rates with standard sequencing. However, approximately 20% of VHL pathogenic variants are partial or complete gene deletions. Standard short-read sequencing excels at detecting point mutations and small insertions/deletions but struggles with large structural rearrangements. Many commercial panels do not include deletion/duplication analysis for VHL — requiring separate, often cumbersome testing. Mosaic VHL variants at low allelic fractions may be missed by standard sequencing depth. Whole genome sequencing detects both point mutations and structural variants in a single analysis.

A VHL finding opens a surveillance protocol that saves lives

Confirmation of VHL triggers the most comprehensive single-gene surveillance protocol in medical genetics. Annual retinal exams from age 1 catch optic pathway complications early. Annual abdominal MRI from age 15 detects kidney cancers and pheochromocytomas at early stages — when kidney-sparing surgery preserves renal function across multiple operations spanning a lifetime. Belzutifan (Welireg), an FDA-approved HIF-2α inhibitor, offers targeted therapy specifically for VHL-associated renal cell carcinoma, representing a genotype-matched treatment option.

Tumors starting in organs that shouldn't be making them — kidneys, spine, eyes. One gene, inherited since birth, determining your lifetime.